[Relationship between myocardial microRNA-30a expression and myocardial fibrosis in rats post myocardial infarction]

L W Chen1, L L Zhu, Q Ji

  • 1Department of Cardiology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China.

Abstract

Insights

MicroRNA-30a (miR-30a) levels decrease after myocardial infarction (MI), promoting fibrosis. Overexpressing miR-30a may suppress this fibrosis by targeting TGF-β1 and CTGF, offering a potential therapeutic strategy.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Biomedical Science

Background:

  • Myocardial infarction (MI) often leads to myocardial fibrosis, a significant cause of heart dysfunction.
  • MicroRNAs (miRNAs) play crucial roles in post-MI cardiac remodeling and fibrosis.
  • Understanding the specific roles of miRNAs like miR-30a is vital for developing targeted therapies.

Purpose of the Study:

  • To investigate the role and mechanism of microRNA-30a (miR-30a) in the development of myocardial fibrosis following myocardial infarction (MI).
  • To explore whether modulating miR-30a levels can impact fibrotic processes in the infarcted heart.

Main Methods:

  • Rats underwent left anterior descending coronary artery ligation to induce MI, with groups assessed at 1, 2, and 4 weeks post-MI.
  • Echocardiography monitored heart function, while Masson staining assessed collagen volume fraction (CVF).
  • Immunohistochemistry, RT-qPCR, and Western blot analyzed collagen expression, and miR-30a, TGF-β1, and CTGF levels.

Main Results:

  • MI induced significant cardiac dysfunction, increased myocardial CVF, and elevated collagen I and III expression in a time-dependent manner.
  • miR-30a levels were significantly reduced post-MI, while mRNA and protein levels of TGF-β1 and CTGF were significantly increased.
  • The collagen I/III ratio increased significantly at 2 and 4 weeks post-MI.

Conclusions:

  • Reduced miR-30a expression is associated with the progression of myocardial fibrosis after MI.
  • Modulating miR-30a levels, potentially through overexpression, could be a therapeutic strategy to suppress myocardial fibrosis.
  • Targeting the TGF-β1 and CTGF pathways offers a mechanism for miR-30a's antifibrotic effects.